Patients with myelofibrosis and anemia respond to antihemojuvelin drug
The investigational drug blocks the expression of HJV in order to reduce hepcidin. It is in mid-stage development by Disc Medicine. Updated data
EHA 2026
ASCO 2026
Meetings / Conferences
Myeloproliferative Neoplasms
ASCO 2026
Acute Myeloid Leukemia
News
Which AML patients get lasting benefit from olutasidenib?
In an analysis presented at ASCO 2026, Justin Watts, MD, of the University of Miami and colleagues explored what baseline factors — including
ASCO 2026
Cellular Therapy
News
Data support COVID-19 vaccination in patients receiving CAR-T therapy
There have been concerns about whether vaccines work well in patients who have received CAR-T therapy and whether vaccination would increase the risk